IL105693A0 - Pyridino-,pyrrolidino-and azepino-substituted oximes useful as anti-atherosclerosis and antihypercholesterolemic agents - Google Patents

Pyridino-,pyrrolidino-and azepino-substituted oximes useful as anti-atherosclerosis and antihypercholesterolemic agents

Info

Publication number
IL105693A0
IL105693A0 IL105693A IL10569393A IL105693A0 IL 105693 A0 IL105693 A0 IL 105693A0 IL 105693 A IL105693 A IL 105693A IL 10569393 A IL10569393 A IL 10569393A IL 105693 A0 IL105693 A0 IL 105693A0
Authority
IL
Israel
Prior art keywords
atherosclerosis
azepino
pyridino
pyrrolidino
substituted oximes
Prior art date
Application number
IL105693A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of IL105693A0 publication Critical patent/IL105693A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL105693A 1992-06-17 1993-05-13 Pyridino-,pyrrolidino-and azepino-substituted oximes useful as anti-atherosclerosis and antihypercholesterolemic agents IL105693A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90022992A 1992-06-17 1992-06-17

Publications (1)

Publication Number Publication Date
IL105693A0 true IL105693A0 (en) 1993-09-22

Family

ID=25412199

Family Applications (1)

Application Number Title Priority Date Filing Date
IL105693A IL105693A0 (en) 1992-06-17 1993-05-13 Pyridino-,pyrrolidino-and azepino-substituted oximes useful as anti-atherosclerosis and antihypercholesterolemic agents

Country Status (13)

Country Link
US (3) US5565468A (xx)
EP (1) EP0649425B1 (xx)
JP (1) JPH07507796A (xx)
CN (1) CN1081678A (xx)
AT (1) ATE177426T1 (xx)
AU (1) AU4293393A (xx)
DE (1) DE69323883T2 (xx)
DK (1) DK0649425T3 (xx)
ES (1) ES2130269T3 (xx)
GR (1) GR3029946T3 (xx)
IL (1) IL105693A0 (xx)
MX (1) MX9303594A (xx)
WO (1) WO1993025553A1 (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
CZ301491B6 (cs) * 2001-04-27 2010-03-24 Eisai R&D Management Co., Ltd. Pyrazolo[1,5-a]pyridiny a léciva s jejich obsahem
SK287857B6 (sk) * 2001-05-24 2012-01-04 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents
JP4322211B2 (ja) * 2002-10-22 2009-08-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 ７−フェニルピラゾロピリジン化合物
US7176216B2 (en) * 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
WO2007008529A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc Celullar cholesterol absorption modifiers
US7501438B2 (en) 2006-07-07 2009-03-10 Forest Laboratories Holdings Limited Pyridoimidazole derivatives
AU2008273050A1 (en) * 2007-07-11 2009-01-15 Auckland Uniservices Limited Pyrazolo[1,5-a]pyridines and their use in cancer therapy
BRPI0911659B8 (pt) * 2008-04-15 2021-05-25 Eisai R&D Man Co Ltd composto 3-fenilpirazolo[5,1-b]tiazol e composição farmacêutica compreendendo o mesmo
AR078521A1 (es) * 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
WO2011043387A1 (ja) * 2009-10-08 2011-04-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロオキサゾール化合物
ES2750956T3 (es) 2014-02-13 2020-03-30 Incyte Corp Ciclopropilaminas como inhibidores de LSD1
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
SG11201606689VA (en) 2014-02-13 2016-09-29 Incyte Corp Cyclopropylamines as lsd1 inhibitors
CN103980281B (zh) * 2014-05-27 2016-06-08 天津市斯芬克司药物研发有限公司 一种咪唑吡嗪化合物及其制备方法
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
NZ735998A (en) 2015-04-03 2024-08-30 Incyte Holdings Corp Heterocyclic compounds as lsd1 inhibitors
NZ740186A (en) 2015-08-12 2024-07-05 Incyte Holdings Corp Salts of an lsd1 inhibitor
AR109452A1 (es) 2016-04-22 2018-12-12 Incyte Corp Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1600969A (en) * 1977-01-07 1981-10-21 Acf Chemiefarma Nv Heterocyclic compounds
US4352804A (en) * 1978-07-25 1982-10-05 Acf Chemiefarma Nv Oxime ethers, their preparation and pharmaceutical compositions containing them
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines

Also Published As

Publication number Publication date
ES2130269T3 (es) 1999-07-01
GR3029946T3 (en) 1999-07-30
US5597816A (en) 1997-01-28
US5565468A (en) 1996-10-15
JPH07507796A (ja) 1995-08-31
DE69323883D1 (de) 1999-04-15
CN1081678A (zh) 1994-02-09
US5523318A (en) 1996-06-04
EP0649425A1 (en) 1995-04-26
ATE177426T1 (de) 1999-03-15
DK0649425T3 (da) 1999-09-27
DE69323883T2 (de) 1999-07-22
AU4293393A (en) 1994-01-04
EP0649425B1 (en) 1999-03-10
WO1993025553A1 (en) 1993-12-23
MX9303594A (es) 1994-01-31

Similar Documents

Publication Publication Date Title
IL105693A0 (en) Pyridino-,pyrrolidino-and azepino-substituted oximes useful as anti-atherosclerosis and antihypercholesterolemic agents
EP0695224A4 (en) COMPOSITIONS AND METHODS FOR TREATING WASTE
IL104289A0 (en) Process and uses for 4,5-dihydrogel-danamycin and its hydroquinone
BG103170A (en) Polymorphic form ii of finasteride and method for its preparation
AU3914493A (en) Process and machines for transforming household waste
AU4598796A (en) Improved method for the treatment and stabilization of hazardous waste
GB9310659D0 (en) Culturing of micro-organisms
AU4520893A (en) Sterilization process and composition
GR3020689T3 (en) Pyrrole derivatives
AU5159493A (en) Hazardous waste transportation and disposal
AU5271593A (en) Apparatus and methods for the utilization of combustible materials especially of industrial and household waste
AU657439B2 (en) Enhancer for the antianemia effect of erythropoietin and method of augmenting the antianemia effect of erythropoietin
AU7122891A (en) Oxetanones
AU4532893A (en) Antihypercholesterolemic compounds and related pharmaceutical compositions and methods of use
GR3026134T3 (en) 4-hydroxy-phenyl-beta-d-glucose monoesters, their method of preparation and their use in the cosmetic, dental-care, pharmaceuticals and food stuff fields.
AU3162093A (en) Process for processing and destroying domestic and/or industrial waste and fuel produced from such waste
FR2709114B1 (fr) Armoire de tri pour recyclage des déchets.
AU5538794A (en) Biologically active compounds and process therefor
AU1414995A (en) Residue and waste treatment process
HK72597A (en) Elimination of scanning disturbances
GB2246955B (en) Destruction of microorganisms
TW340108B (en) 1,1-difluoro-1,4-dichlorobutane and process for its preparation
AU5093993A (en) Nonionic X-ray contrast agents compositions and methods
PL312966A1 (en) Derivatives of thiocarbamoil
AP9600790A0 (en) Process for preparation of substituted steroidal dienes and novel intermediates used in said process.